Syndax Pharmaceuticals reported an 82% year-over-year revenue increase to $83.3 million in the third quarter of 2026, primarily driven by a 90% growth in sales of its drug Revuforj. Despite higher research and development expenses, the company narrowed its operating losses. Management sees potential for extended treatment duration with Revuforj due to post-transplant maintenance trends, which could boost revenue further if more patients resume treatment. The company maintains a Hold rating, balancing strong cash reserves and reasonable valuation against risks tied to clinical trial outcomes and market expansion for acute myeloid leukemia (AML) treatments.
Syndax Pharmaceuticals' recent commercial growth contrasts with broader health sector trends on Pluang. As of Nov 04, 2026 20:41 WIB, 127 of 150 health-sector stocks rose while 19 fell. Among notable movers, CVS Health Corp declined 4.93% to USD 86.90 with a typical hold time of 81 days and a strong buy order activity of 91%, whereas Tilray Brands Inc gained 4.91% to USD 2.78 but saw 96% sell orders with a shorter hold time of 32 days. Alcon AG rose 4.34% to USD 75.51 with 91% sell orders and a 72-day hold time.
Goldman Sachs Group, Inc. disclosed that it briefly held a combined stake exceeding 3% in Ontex Group NV shares as of October 27, 2026, with 566,115 voting rights and 1,965,157 financial instruments. However, by October 28, 2026, their combined posit...
BNP Paribas announced its monthly declaration of voting rights and shares as of October 31, 2026. The bank reported a total of 1,101,600,607 shares and an equal number of voting rights. This update is part of regulatory compliance under French commer...
Ontex disclosed that Goldman Sachs Group, Inc. crossed the 3% ownership threshold in Ontex shares on October 27, 2026, holding a combined total of 3.07% including voting rights and financial instruments. However, the next day, October 28, 2026, Goldm...
Neion Bio has appointed John A. Maga, Ph.D., as Head of Biologics and CMC to lead the development of biologic medicines using its Raptor platform, which produces proteins in transgenic chicken eggs. Maga brings over 25 years of biopharmaceutical expe...
The National Advertising Division (NAD) recommended that Good Life Meds discontinue claims about health benefits and personalization for its compounded Tirzepatide+ weight loss products after a challenge by Eli Lilly. NAD found that Good Life lacked ...
